Shots:

•  Results of Ph 3 GENESIS trial comparing combination of BL-8040 plus G-CSF vs. G-CSF in multiple myeloma patients
•  GENESIS is an open-label- single-arm study with 30 patients. First 11 patients showed safety and tolerability
• Results: In trial 9/11 (82%) showed ≥6x10⁶CD34 cells/kg after 2 apheresis; 7/11 (64%)- showed ≥6x10⁶ CD34 cells/kg post 1 session- which lead to reduction in treatment cost and better QoL

Ref: Biolinerx | Image: LinkedIn